Patents by Inventor Seul Ah CHUN

Seul Ah CHUN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME
    Publication number: 20240239782
    Abstract: The present invention relates to a sulfate crystal form of a compound represented by formula 1, a method of producing same, and a pharmaceutical composition comprising same. The sulfate crystal form of the compound represented by formula 1 of the present invention may be characterized by an XRPD pattern, a DSC profile, and/or a TGA profile.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 18, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Seul Ah CHUN, Sung Won KIM
  • CO-CRYSTAL OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND VANILLIN AND METHOD FOR PREPARING SAME
    Publication number: 20240239769
    Abstract: The present invention relates to a co-crystal of a compound represented by chemical formula 1 and vanillin, a method for preparing same, and a pharmaceutical composition comprising same. The co-crystal of the compound represented by chemical formula 1 and vanillin of the present invention has excellent chemical and physical stability and is characterized by the XRD pattern, DSC profile, and/or TGA profile.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 18, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Seul Ah CHUN, Sung Won KIM
  • CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME
    Publication number: 20240239783
    Abstract: The present invention relates to a crystal form VII of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The crystal form VII of the compound represented by chemical formula 1, according to the present invention, can be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 18, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ho Yeon LEE, Jin Ok HAM, Sang Dae LEE, Ji Yoon KIM, Jong Won PARK, Sung Won KIM, Seul Ah CHUN
  • CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME
    Publication number: 20240228473
    Abstract: The present invention relates to a crystalline form V of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form V of the compound represented by chemical formula 1 according to the present invention may be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 11, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Jin Ok HAM, Ho Yeon LEE, Sang Dae LEE, Ji Yoon KIM, Jong Won PARK, Sung Won KIM, Seul Ah CHUN
  • CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF
    Publication number: 20240217954
    Abstract: The present invention relates to a crystal form IV of organic acid salts of a compound represented by chemical formula 1, a preparation method thereof, and a pharmaceutical composition comprising same. The crystal form IV of organic acid salts of the compound represented by chemical formula 1 of the present invention may be characterized by an XRPD pattern, a DSC profile, and/or a TGA profile.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 4, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Seul Ah CHUN, Sung Won KIM
  • CRYSTALLINE FORM OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST
    Publication number: 20240208930
    Abstract: The present invention relates to a crystalline form of a sphingosine-1-phosphate receptor agonist and, more particularly, to a crystalline form0- of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid of chemical formula 1 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 13, 2022
    Publication date: June 27, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Seul Ah CHUN, Sung Wook KIM, Sung Won KIM, Ki Dae KIM, Soo Min LEE
  • AMORPHOUS MELANOCORTIN RECEPTOR AGONIST AND METHOD FOR PREPARING SAME
    Publication number: 20240059652
    Abstract: The present invention relates to an amorphous compound represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The amorphous compound represented by formula 1 of the present invention may be characterized by XPRD patterns, DSC profiles, and/or a NMR spectrum.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 22, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Seung Wan KANG, Seul Ah CHUN, Sung Won KIM
  • CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20240051919
    Abstract: The present invention relates to a crystalline form III represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form III represented by formula 1 of the present invention may be characterized by XRPD patterns, TG/DTA profiles, an NMR spectrum, and/or DVS profiles.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 15, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Seul Ah CHUN, Sung Won KIM
  • CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20240051944
    Abstract: The present invention relates to a crystalline form II represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form II represented by formula 1 of the present invention may be characterized by XRPD patterns, DSC profiles, TGA profiles, and/or DVS profiles.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 15, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Ho Yeon LEE, Jin Ok HAM, Seul Ah CHUN, Sung Won KIM
  • CRYSTALLINE FORM I OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME
    Publication number: 20240043407
    Abstract: The present invention relates to a crystalline form I represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form I represented by formula 1 of the present invention may be characterized by XRPD patterns, DSC profiles, TGA profiles, and/or DVS profiles.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 8, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Ji Yoon KIM, Sang Dae LEE, Ri Ra KIM, Sung Won KIM, Ho Yeon LEE, Seul Ah CHUN, Jin Ok HAM
  • CRYSTALLINE FORM IV OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20240010633
    Abstract: The present invention relates to a crystalline form IV represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form IV represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
    Type: Application
    Filed: October 29, 2021
    Publication date: January 11, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Jin Ok HAM, Ho Yeon LEE, Ji Yoon KIM, Sung Won KIM, Seul Ah CHUN, Sang Dae LEE, Jong Won PARK
  • CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20230399321
    Abstract: The present invention relates to a crystalline form II represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form II represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
    Type: Application
    Filed: October 29, 2021
    Publication date: December 14, 2023
    Applicant: LG CHEM, LTD.
    Inventors: Jin Ok HAM, Ho Yeon LEE, Ji Yoon KIM, Sung Won KIM, Seul Ah CHUN, Sang Dae LEE, Jong Won PARK
  • CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20230382895
    Abstract: The present invention relates to a crystalline form III represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form III represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
    Type: Application
    Filed: October 29, 2021
    Publication date: November 30, 2023
    Applicant: LG CHEM, LTD.
    Inventors: Jin Ok HAM, Ho Yeon LEE, Ji Yoon KIM, Sung Won KIM, Seul Ah CHUN, Sang Dae LEE, Jong Won PARK
  • CRYSTALLINE FORM I OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20230373984
    Abstract: The present invention relates to a crystalline form I represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form I represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
    Type: Application
    Filed: October 29, 2021
    Publication date: November 23, 2023
    Applicant: LG CHEM, LTD.
    Inventors: Jin Ok HAM, Ho Yeon LEE, Ji Yoon KIM, Sung Won KIM, Seul Ah CHUN, Sang Dae LEE, Jong Won PARK